Dr Fred Bosman
Director of the University Institute of Pathology at the
University Medical Center (CHUV) of Lausanne in Switzerland
and Professor of Pathology at Faculty of Biology and Medicine
of the University of Lausanne
Institut Universitaire de Pathologie
Rue du Bugnon 25
1011 Lausanne
Switzerland
Tel.: +41 21 314 7202
Fax: +41 21 314 72 05
E-mail: Fred.Bosman@chuv.ch

Academic degrees
MD, University of Leiden, The Netherlands (1971),
PhD, University of Leiden, The Netherlands (1976)
Trainer as a pathologist, University of Leiden, The Netherlands.
Staff pathologist at the University of Leiden (1975-1981)
Lecturer at the University of Surinam (1974-1975)
Professor and chair of Pathology at the Faculty of Medicine of the University of Maastricht (1981-1990) and at the Faculty of Medicine of the Erasmus University in Rotterdam (1990-1995)

Prizes and honors
Honorary Fellow of the Royal College of Pathologists (UK)
President of the Dutch Society for Pathology
Vice-dean of the Faculty of Medicine in Maastricht
Chairman of the Science Review Committee of the Faculty of Medicine in Rotterdam
President of the Society for Histochemistry
President of the European Society of Pathology
Member of the Scientific Advisory Board of several renowned Research Institutes
Former Vice-President of Oncosuisse, the Swiss Organisation for the fight against cancer

Editorial board
Former Associate Editor of the Journal of Pathology and presently Editor in Chief of Virchows Archiv
Section Editor ‘Gastro-Intestinal Pathology’ for a new online Textbook of Pathology.

Series-coeditor of the 4th edition WHO Series ‘Classification of Human Tumours’, the international standard for tumour classification

Selected publications

Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, Delorenzi M, Bosman FT, Roth AD, Yan P, Bougel S, Di Narzo AF, Popovici V, Budinská E, Mao M, Weinrich SL, Rejto PA, Hodgson JG. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS One. 7:e42001. (2012)

Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 30:1288-95 (2012)

Tejpar S, Saridaki Z, Delorenzi M, Bosman F, Roth AD. J Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst. 103:841-4. (2011)

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol.28:466-74 (2010)

Ensari A, Bosman FT, Offerhaus GJ. The serrated polyp: getting it right! J Clin Pathol.;63:665-8 (2010)

Bosman FT, Yan P, Tejpar S, Fiocca R, Van Cutsem E, Kennedy RD, Dietrich D, Roth A. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res.;15:5528-33 (2009)

van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453:417-31 (2008)

Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene. 25:3084-92 (2006)

Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol. 208:100-7 (2006)

Sordat I, Rousselle P, Chaubert P, Petermann O, Aberdam D, Bosman FT, Sordat B. Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer. 1;88:708-17 (2000)

Selected text books

Bosman FT Molecular Pathology of Colorectal Cancer. In: Molecular Genetic Pathology (Ed L.Cheng.) 2nd Edition, Springer 2013

Bosman FT, Carneiro F, R Rhuban, N Theise (Eds) WHO Classification of Tumours of the Digestive System IARC, Lyon, 2010

Fred T Bosman Cancer Invasion and metastasis: the concept of Epithelial Mesenchymal Transition. In Recent Advances in Histopathology Vol.22 (Ed. J Underwood, M Pignatelli), Royal Society of Medicine Press 2007, 67-80

Fred T Bosman Pathology. In: Nursing Patients with Cancer (Eds.N Kearney, A Richardson) Elsevier, 2006, 97-115